Leah Kuntz

Researchers unveil a groundbreaking nasal spray using lithium-loaded gold nanoparticles, targeting brain diseases with reduced adverse effects.

This infographic can help you review 6 highlights from the INTEGRATE Guidelines.

Reproductive psychiatrist Sarah Oreck, MD, MS challenges the FDA's claims linking acetaminophen use in pregnancy to autism and ADHD, advocating for informed maternal care.

The Ububele Educational and Psychotherapy Trust enhances mental health access in South Africa, focusing on early childhood support and community-based interventions to break cycles of emotional poverty.

Bristol Myers Squibb's BMS-986446 receives FDA Fast Track Designation, aiming to transform early Alzheimer disease treatment by targeting tau pathology.

Explore how lifestyle choices like diet, exercise, and sleep enhance mental health outcomes in psychiatry. Share your insights and experiences today with our October theme!

Lipocine Inc. advances LPCN 1154, an oral treatment for postpartum depression, aiming for rapid relief and improved patient access by 2026.

What disease states are most prominently featured in recent research? Learn more in this exclusive article.

New phase 3 data highlights seltorexant's potential as a safer adjunctive treatment for major depressive disorder with insomnia, despite not meeting primary end points. Andrew J. Cutler, MD, shares his thoughts.

INmune Bio reveals phase 2 trial results for XPro1595, a novel treatment targeting neuroinflammation in early Alzheimer disease.

A new study reveals tasimelteon (Hetlioz) significantly improves sleep onset in chronic insomnia patients.

Synendos Therapeutics reveals promising phase 1 results for SYT-510, a novel ECS modulator targeting anxiety and CNS disorders with potential for improved patient outcomes.

New analysis reveals Ingrezza achieves rapid symptomatic remission in tardive dyskinesia, enhancing patient quality of life and reducing disease burden.

New phase 2a study reveals promising results for BPL-003, with a 2-dose regimen improving outcomes for patients with treatment-resistant depression.

New phase 3 data reveals seltorexant's potential as a safer adjunctive treatment for major depressive disorder with insomnia, despite not meeting its primary end point.

Adial Pharmaceuticals has received feedback from FDA on the AD04 phase 3 adaptive clinical trial design and broader clinical development strategy.

Oregon's "Create Resilience" Youth Art Contest celebrates creativity in mental health, showcasing powerful youth submissions that inspire hope and connection.

Christine Yu Moutier, MD, discusses suicide prevention strategies, highlighting risk factors and the importance of culturally competent care for vulnerable populations.

New research reveals ART12.11, a cannabidiol:tetramethylpyrazine cocrystal, significantly enhances mood regulation, outperforming traditional cannabidiol in treating mood and anxiety disorders.

Alto Neuroscience reveals EEG biomarkers effectively distinguish patients with schizophrenia, enhancing treatment precision and advancing psychiatric research.

Tonmya, the first new FDA-approved fibromyalgia treatment in 15 years, shows promise in reducing pain and improving patient outcomes according to newly released data.

Alixorexton shows promise as a treatment for narcolepsy type 1, and is the first orexin 2 receptor agonist to demonstrate clinically meaningful and statistically significant impact on wakefulness, cognition, and fatigue with once-daily dosing across a range of doses.

Neuphoria Therapeutics announces successful enrollment in a pivotal trial for BNC-210, a promising treatment for social anxiety disorder.

A new guideline from the APA enhance the prevention and treatment of delirium, aiming to improve patient care and outcomes in clinical settings.

Submit to our September theme: Diagnosis Dilemmas!

Check out the pipeline updates from August!

BioXcel Therapeutics reveals promising phase 3 results from the SERENITY trial, paving the way for potential at-home treatment of agitation in bipolar disorder and schizophrenia.

Incannex Healthcare shared positive data from its phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for generalized anxiety disorder.

Leqembi for the treatment of Alzheimer disease has been launched in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025—the first launches in the EU.

Altimmune's pemvidutide gains FDA Fast Track designation for alcohol use disorder.